You are here:

clostridium botulinum type A neurotoxin (Botox)


following a second re-submission

Botulinum toxin type A (Botox®) is accepted for use within NHS Scotland.

Indication under review: focal spasticity, including the treatment of wrist and hand disability due to upper limb spasticity associated with stroke in adults.

In a placebo-controlled study, botulinum toxin type A was significantly superior to placebo in terms of the disability assessment scale and efficacy was maintained across repeated injections in an open-label extension study with a duration of one year.

Drug Details

Drug Name: clostridium botulinum type A neurotoxin (Botox)
SMC Drug ID: 80/03
Manufacturer: Allergan Ltd
Indication: Focal spasticity of the wrist and hand associated with stroke in adults.
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 7 March 2011

Archived Advice

Resubmission 10 May 2004
Full submission 10 November 2003